Sarepta Therapeutics (SRPT) Competitors $39.07 -0.64 (-1.61%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$39.21 +0.14 (+0.36%) As of 06/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SRPT vs. ITCI, GMAB, SMMT, RDY, ASND, MRNA, VTRS, QGEN, BPMC, and ROIVShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. Intra-Cellular Therapies Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Moderna Viatris Qiagen Blueprint Medicines Roivant Sciences Sarepta Therapeutics (NASDAQ:SRPT) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability. Is SRPT or ITCI more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Intra-Cellular Therapies' net margin of -14.07%. Sarepta Therapeutics' return on equity of 11.00% beat Intra-Cellular Therapies' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do insiders and institutionals have more ownership in SRPT or ITCI? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor SRPT or ITCI? In the previous week, Sarepta Therapeutics had 18 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 18 mentions for Sarepta Therapeutics and 0 mentions for Intra-Cellular Therapies. Sarepta Therapeutics' average media sentiment score of 0.53 beat Intra-Cellular Therapies' score of 0.00 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sarepta Therapeutics Positive Intra-Cellular Therapies Neutral Which has better earnings & valuation, SRPT or ITCI? Intra-Cellular Therapies has lower revenue, but higher earnings than Sarepta Therapeutics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$2.23B1.72-$535.98M-$2.69-14.52Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Does the MarketBeat Community believe in SRPT or ITCI? Sarepta Therapeutics received 961 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 75.01% of users gave Sarepta Therapeutics an outperform vote while only 65.74% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes148375.01% Underperform Votes49424.99% Intra-Cellular TherapiesOutperform Votes52265.74% Underperform Votes27234.26% Do analysts recommend SRPT or ITCI? Sarepta Therapeutics presently has a consensus price target of $122.61, indicating a potential upside of 213.82%. Intra-Cellular Therapies has a consensus price target of $109.70, indicating a potential downside of 16.81%. Given Sarepta Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 0 Sell rating(s) 4 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.87Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Which has more risk & volatility, SRPT or ITCI? Sarepta Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. SummarySarepta Therapeutics beats Intra-Cellular Therapies on 14 of the 19 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.84B$6.83B$5.57B$8.66BDividend YieldN/A2.50%5.27%4.19%P/E Ratio31.268.7927.2020.17Price / Sales1.72263.51412.92161.90Price / CashN/A65.8538.2534.64Price / Book4.256.677.114.72Net Income-$535.98M$143.49M$3.23B$247.80M7 Day Performance0.51%6.34%4.61%3.36%1 Month Performance7.72%15.43%13.35%9.71%1 Year Performance-68.13%6.87%31.75%14.41% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.8483 of 5 stars$39.07-1.6%$122.61+213.8%-68.1%$3.84B$2.23B31.26840ITCIIntra-Cellular Therapies0.9186 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560GMABGenmab A/S3.285 of 5 stars$21.77+3.9%$39.17+79.9%-18.2%$13.96B$3.12B12.511,660Positive NewsGap UpSMMTSummit Therapeutics3.0215 of 5 stars$17.73-2.7%$37.40+110.9%+176.7%$13.17B$700,000.00-63.32110Analyst RevisionGap UpHigh Trading VolumeRDYDr. Reddy's Laboratories1.2625 of 5 stars$14.73+0.0%$17.00+15.4%+9.5%$12.29B$325.54B23.4524,800ASNDAscendis Pharma A/S3.3978 of 5 stars$175.69+7.9%$216.07+23.0%+31.1%$10.71B$368.70M-24.75640Positive NewsAnalyst ForecastAnalyst RevisionMRNAModerna4.4393 of 5 stars$27.05+1.8%$53.58+98.1%-81.4%$10.46B$3.14B-2.913,900Trending NewsVTRSViatris2.2307 of 5 stars$8.69-1.1%$10.50+20.8%-14.0%$10.20B$14.33B-11.7437,000QGENQiagen3.1885 of 5 stars$44.89-0.5%$48.42+7.9%+6.0%$9.98B$2.00B125.006,030BPMCBlueprint Medicines0.9378 of 5 stars$127.79+26.1%$125.69-1.6%+23.0%$8.25B$562.12M-118.32640High Trading VolumeROIVRoivant Sciences2.3791 of 5 stars$11.17+1.6%$17.50+56.7%+7.5%$7.97B$29.05M-74.46860 Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Summit Therapeutics Competitors Dr. Reddy's Laboratories Competitors Ascendis Pharma A/S Competitors Moderna Competitors Viatris Competitors Qiagen Competitors Blueprint Medicines Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SRPT) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SRPT Stock Free SRPT Stock Alerts